Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma

Inclusion Criteria:

* Histologically verified gastric carcinoma of advanced stages which is unsuitable for surgery;
* No prior systemic chemotherapy with taxane at least 6 months before the recruitment;
* At least one measurable tumor according to RECIST standard, with at least one diameter ≥20mm assessed by traditional imaging technique or MRI, or with a diameter twice of the thickness of scan layer (or ≥10-16mm) under spiral CT; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1;
* Patients who are expected to live at least 3 months;
* Obtaining informed consent;

Exclusion Criteria:

* Receiving other chemotherapy or radiotherapy during the administration;
* Symptomatic metastatic brain tumor;
* Allergy to any study medication;
* Pregnancy or breast feeding;
* Severe heart diseases;
* Uncontrolled mental diseases;
* Abnormal liver and renal functions, which are measured by AST/ALT and BUN/Cr;
* Neutrophils（ANC）\<2000/μL;platelets\<100，000/μL;hemoglobin（HB）\<9.0 g/dL;